Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.
about
Toward precision medicine in Alzheimer's diseaseRole of Hybrid Brain Imaging in Neuropsychiatric DisordersAnti-dementia medications: current prescriptions in clinical practice and new agents in progressA genetic cause of Alzheimer disease: mechanistic insights from Down syndromeAutosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical ADThe Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriersGenetic heterogeneity in Alzheimer disease and implications for treatment strategiesHarnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and ChallengesThree dimensions of the amyloid hypothesis: time, space and 'wingmen'Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study GroupTemplate based rotation: a method for functional connectivity analysis with a priori templatesUse of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials.Study protocol: Insight 46 - a neuroscience sub-study of the MRC National Survey of Health and Development.An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.The evolution of preclinical Alzheimer's disease: implications for prevention trials.Fitting the epidemiology and neuropathology of the early stages of Alzheimer's disease to prevent dementiaWhere is hippocampal activity in the cascade of Alzheimer's disease biomarkers?Endpoints in preclinical Alzheimer's disease trials.A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease.Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force.The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target PopulationsBivariate correlation coefficients in family-type clustered studiesPrecision Medicine: Clarity for the Complexity of Dementia.Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.CAP--advancing the evaluation of preclinical Alzheimer disease treatments.δ-COP modulates Aβ peptide formation via retrograde trafficking of APPSensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score.Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis.Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.Benefits and risks of add-on therapies for Alzheimer's disease.Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.Familial Presenilin Mutations and Sporadic Alzheimer's Disease Pathology: Is the Assumption of Biochemical Equivalence Justified?Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.Advances in the genetics of schizophrenia: toward a network and pathway view for drug discovery.Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.
P2860
Q26748939-D4E58DED-BC18-4CB8-884D-243CC82171F4Q26768454-AA192396-4B33-4276-A8D0-D1A3B1906A19Q26795400-B288D04D-80A5-4821-9EF4-60E2E4B842BCQ26798983-301E5E65-E097-4636-A549-135158264B5CQ26801666-96B0DB50-A484-4E01-8E56-AB2D210FEF16Q26849380-BF9A2BE4-7EE8-4025-844A-D1549848253AQ26995802-E1CBCF0C-3E84-4CF0-9352-800C1596FA4AQ28072061-14D93638-5064-49F7-B390-5C46FC986FAEQ28082768-00B3D69F-9D1B-4ED5-B14E-E7D6A0F22F25Q28550984-0BCC7279-741D-420B-A756-1EA13D85FBA7Q28650529-189A609F-1928-4131-B564-344401393D46Q30994007-EDC4E8CE-EEAF-4921-AEB9-E15720FFB502Q33576727-F7675A06-80FB-4277-A591-D50F4F04A08FQ34364368-1654E3D4-480E-4F39-871F-66FC55556B70Q34849048-3B1D21BA-3317-4526-B61A-4E5D2DFE2A2DQ35114370-B4A2C49F-E24E-49F5-86B4-C7E920A46175Q35626515-BF25E340-8029-4334-A00B-B9BAEFBC8323Q35694848-5406A8C1-5723-4B51-9FF0-C25785AB487FQ35879102-88763DB9-7809-4B4F-9F40-D9DD6D7864A5Q35910923-8B08D791-3DC9-4272-896A-4E9E8F8ADCC3Q36165011-3AAAD28D-9995-4DE6-A627-E55056825B87Q36543670-F30735A1-DD21-4489-8731-B15CBDE3F169Q36753680-5C5E2A4E-F806-4EDE-AAB1-0689015285B4Q36764094-6251706F-EA15-444F-8A21-CBE18F06115AQ36843004-11A3A41A-05C3-4618-85CF-3F133E4320E1Q36905030-EB870B89-6A5A-4A9D-B4E8-11AE40C94FBCQ36934154-809F43B7-81E2-4EAF-8F5A-E0F34B4BD3A7Q38220107-1228240D-ADB9-4805-BD29-9C08487F0D3BQ38224958-AD2204F0-E023-4560-88A7-A88EF16BEB9BQ38235780-88BA2D77-AA8C-47DB-8D5C-F7701C5ED866Q38620338-C47CD846-5D17-4307-A44E-B1FD60B33567Q38657224-9599AE4F-E258-43C1-8B03-D55C4C1D3E81Q38693441-2AA8E59A-8FFD-4A6B-BBC0-FD7730FA60A3Q38719665-C0F82AEF-63C5-453B-BA76-110B1CB277D6Q38816605-3B2E5055-D00D-4B74-9578-58440CA53D71Q38933111-FBF9E134-21AF-4FC5-B14A-C76C19F23BB6Q38966308-2D0061A6-D257-4D60-8D6C-AD1AFDF286BFQ38983318-6FF8EA8F-9358-47C8-979D-140A2B37A105Q39432793-395C9A7B-7E49-4037-9D40-BC221C881F92Q39493228-186B47D0-D021-4B52-8E53-90BD2CF8A4C5
P2860
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.
@ast
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.
@en
type
label
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.
@ast
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.
@en
prefLabel
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.
@ast
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.
@en
P2093
P2860
P50
P1433
P1476
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial
@en
P2093
A M Santacruz
C M Masters
P2860
P304
P356
10.1016/J.NEUROL.2013.07.017
P50
P577
2013-09-06T00:00:00Z